| FDA Panel Vote Weighs in Favor of Alkermes Psych Drug, With Caveats | Frank Vinluan | 10/09/20 | Europe |
| Bio Roundup: Sarepta’s Approval, Merck M&A, Drug Price Bill & More | Frank Vinluan | 12/13/19 | National |
| Bio Roundup: So Long Celgene, RNAi’s Arrival, Pharma in 2020 & More | Frank Vinluan | 11/22/19 | National |
| Alkermes Eyes Brain Disorders and Beyond With $100M Deal for Rodin | Frank Vinluan | 11/18/19 | Boston |
| Biotech Roundup: Novartis on Hold, AMAG Vote, Neuro News & More | Frank Vinluan | 11/01/19 | National |
| The Placebo Effect Is Hobbling New Psychiatric Drugs. What Can Stop It? | Alex Lash | 10/10/19 | National |
| Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More | Frank Vinluan | 09/27/19 | National |
| Biogen, Taking Its Crisis “Seriously,” Keeps Focus on Neuroscience | Ben Fidler | 04/24/19 | Boston |
| Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More | Ben Fidler | 02/08/19 | National |
| FDA Rejects Alkermes Depression Drug, Asks for More Clinical Data | Frank Vinluan | 02/01/19 | Boston |
| Alkermes Schizophrenia Drug Heads To FDA, But Questions Linger | Ben Fidler | 11/29/18 | Boston |
| Expansion Therapeutics Hires Elliot Enrich as CMO | Sarah de Crescenzo | 11/13/18 | San Diego |
| Bio Roundup: Depression Drug Dashed, Peek at ASH, CRISPR Worry & More | Alex Lash | 11/02/18 | National |
| Alkermes Depression Drug Faces Long Odds After FDA Advisors Say No | Ben Fidler | 11/01/18 | Boston |
| FDA Blasts Data, Trial Design For Alkermes Depression Drug | Ben Fidler | 10/30/18 | Boston |
| With $1.6B Armo Buy, Eli Lilly Is the Latest to Bet Big on Cytokines | Frank Vinluan | 05/10/18 | Indiana |
| Bio Roundup: Hope for Lungs, Bradner’s Complaint, FDA Nods & More | Alex Lash | 04/20/18 | National |
| Alkermes Depression Drug Review Goes Ahead After FDA About-Face | Corie Lok | 04/16/18 | Boston |
| Bio Roundup: Ex-Kiters Say Allo, NASH Cash & Data, Alkermes No & More | Alex Lash | 04/06/18 | National |
| FDA Refuses Review of Alkermes Depression Drug, Wants More Trials | Frank Vinluan | 04/02/18 | Boston |
| Sage Shares Soar Again As Depression Drug Hits Mark in Phase 2 Test | Ben Fidler | 12/07/17 | Boston |
| 15 For ’18: Key Clinical Data to Watch For Next Year (Part 2) | Alex Lash | 12/06/17 | National |
| Bio Roundup: Migraine Data, Cancer Drug Combos, Azar Hearing & More | Frank Vinluan | 12/01/17 | National |
| Bio Roundup: Barron Joins GSK, Sage Bounces Back, Valeant Dumps Addyi | Ben Fidler | 11/10/17 | National |
| Bio Roundup: Drug Price Debates, NY Bio Blooms & CEOs Take Social Stand | Frank Vinluan | 08/25/17 | National |
| Side Effect Weighs on Early Results for Alkermes’ Schizophrenia Drug | Frank Vinluan | 06/29/17 | Boston |
| Bio Roundup: Trumpcare Is Mean, SCOTUS Says Go, Merck’s Myeloma No | Ben Fidler | 06/16/17 | National |
| Stifling Immigration Is “Retrograde”: Highlights From “What’s Hot” | Ben Fidler | 05/17/17 | Boston |
| On Tap For “What’s Hot” on May 11: Opioid Crisis, Immigration & More | Ben Fidler | 04/13/17 | Boston |
| Check Out What’s Hot in Boston Biotech on May 11: Saver Rate Ends Today | Ashley Gentile | 04/06/17 | Boston |
